Lilly Aims For Earlier Treatment With Novel Diabetes Drugs

GLP-1/GIP Agonist Tirzepatide Leads Next-Gen Pipeline

Lilly outlined its tirzepatide-led pipeline of incretin agonists and highlighted its once-weekly basal insulin during a post-ADA event. The company hopes to grow the GLP-1 market overall rather than shift patients from Trulicity.

Diabetes; Chalkboard on a wooden background
Lilly is looking beyond diabetes to obesity, NASH and heart failure with its incretin agonists • Source: Alamy

Eli Lilly and Company does not intend to give up Trulicity (dulaglutide) market share to competitors’ glucagon-like peptide 1 (GLP-1) receptor agonists and it does not plan to shift patients from its blockbuster type 2 diabetes band to tirzepatide, if the dual agonist of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) is approved next year. Instead, the company hopes to grow the overall GLP-1 market, in part by increasing prescriptions in the drug class for patients earlier in their treatment.

Lilly executives explained during a 1 July investor event, which followed the American Diabetes Association’s (ADA’s) Scientific Sessions at the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category